WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices. The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading. Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court. |
Mountain goat stuck under Kansas City bridge survives rocky rescueNearly half of the world’s migratory species are in decline, UN report saysUS officials warn of increase in bacterial illnesses that can lead to meningitis and possibly deathVideo from 2022 misrepresented as footage of Baltimore bridge collapseAirplane passenger fined in Sydney for urinating in a cupMedicare can pay for obesity drugs like Wegovy in certain heart patientsThis stinks. A noxious weed forces Arizona national monument's picnic area to close until MayMore than six in 10 US abortions in 2023 were done by medicationConfusion about brand name leads to false claims about Aldi’s baconCicadas are nature's weirdos, and about to infest 2 parts of the U.S.